Zylopred Ophthalmic Suspension is a combination medication containing Gatifloxacin 3 mg and Loteprednol etabonate 5 mg, formulated for the treatment of ocular infections accompanied by inflammation. Gatifloxacin, a fourth-generation fluoroquinolone antibiotic, exhibits broad-spectrum bactericidal activity by inhibiting bacterial DNA gyrase and topoisomerase IV, effectively targeting Gram-positive and Gram-negative pathogens commonly implicated in ocular infections. Loteprednol etabonate, a corticosteroid with potent anti-inflammatory properties, acts by modulating the inflammatory response, reducing ocular redness, swelling, and discomfort. The synergistic effect of these agents makes Zylopred suitable for managing bacterial conjunctivitis, keratitis, and other inflammatory ocular conditions where infection and inflammation coexist. The ophthalmic suspension is administered topically, ensuring localized drug delivery with minimal systemic absorption. It is indicated for patients requiring simultaneous antimicrobial and anti-inflammatory therapy to alleviate symptoms and promote healing. Caution is advised in patients with viral, fungal, or mycobacterial eye infections, as corticosteroids may exacerbate these conditions. Use should be under strict medical supervision, with monitoring for potential adverse effects such as increased intraocular pressure or secondary infections. Zylopred Ophthalmic Suspension offers an effective therapeutic option for comprehensive management of infectious and inflammatory ocular disorders.